New treatment strategy aims to stop rare liver cancer
An OHSU surgeon’s innovative approach targets deadly cholangiocarcinoma of the liver. Jerry Widawski knew the statistics were not in his favor. At age 68, he was diagnosed with a rare...
An OHSU surgeon’s innovative approach targets deadly cholangiocarcinoma of the liver. Jerry Widawski knew the statistics were not in his favor. At age 68, he was diagnosed with a rare...
This week, the OHSU Knight Cancer Institute opened a new, 13,000-square-foot space devoted to serving patients taking part in early-phase clinical trials. The unit completes the build-out of the...
When a new cancer drug improves survival in a clinical trial, it too often remains unclear whether the drug will be effective in clinical practice, asserts a provocative commentary (co-authored by an...
Among 55 cancer drugs recently approved on the basis of a surrogate endpoint, less than one-fifth have been shown to improve survival in follow-up clinical trials. Fully two-thirds of new cancer...